Category

• Pipeline3

Organizations

• Bausch + Lomb64
• Eyes On Eyecare42
• Alcon, Inc.41
• American Optometric Association34
• Harrow26
• Glaukos25
• Regeneron21
• Aldeyra Therapeutics20
• Sight Sciences19
• American Academy Of Ophthalmology18

Tags

• DME3
• AMD2
• FDA2
• Wet Amd2
• Clinical Trials1
• Diabetic Retinopathy1
• Retina1

• Organizations: Bayer AG✕

Clear all

Pipeline

Regeneron releases 2-year data on aflibercept 8 mg for DME

New findings support 1-year data of interval dosing maintenance; shows similarities to Eylea clinical data.

Pipeline

FDA declines BLA approval for Regeneron's high-dose aflibercept

Agency bases response on an ongoing review of inspection findings at a third-party filler. 

Pipeline

FDA grants aflibercept priority review for retinal diseases

Regeneron and Bayer AG are jointly developing aflibercept 8 mg to treat wet AMD, DME, and diabetic retinopathy.